NDA of Rademikibart, Jointly Developed by Simcere and Connect Biopharma for the Treatment of Atopic Dermatitis Accepted by NMPA

QUVIVIQ^® - The World’s New Generation Anti-Insomnia Drug – Approved for Launch，Significantly Improves Sleep and Daytime Functioning

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

Simcere Zaiming and NextCure Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

2025 ASCO | Simcere Zaiming Showcases the Latest Clinical Data in 18 Studies for 5 Innovative Products

Simcere Zaiming Announces Phase 3 Clinical Trial Results for Cetuximab β Injection (Enlituo)

Simcere Zaiming will present 7 innovative researches at the 2025 AACR

Simcere Zaiming’s FGFR2b targeting ADC SIM0686 obtained IND approval from China NMPA

NDA of Deunoxavir Marboxil ,the Next Generation Innovative Influenza Drug get Accepted , Offering Hope for "One-Pill Cure" for Influenza.

All Patients Enrolled in Phase III Clinical Study of Deunoxavir Marboxil for Pediatric Indication